227 related articles for article (PubMed ID: 7902209)
61. Reexpression of the major protein kinase C substrate, SSeCKS, suppresses v-src-induced morphological transformation and tumorigenesis.
Lin X; Gelman IH
Cancer Res; 1997 Jun; 57(11):2304-12. PubMed ID: 9187136
[TBL] [Abstract][Full Text] [Related]
62. Modulation of the transformed and neoplastic phenotype of rat fibroblasts by MHC-I gene expression.
Gattoni-Celli S; Strauss RM; Willett CG; Pozzatti R; Isselbacher KJ
Cancer Res; 1989 Jun; 49(12):3392-5. PubMed ID: 2655894
[TBL] [Abstract][Full Text] [Related]
63. Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a.
Garbisa S; Pozzatti R; Muschel RJ; Saffiotti U; Ballin M; Goldfarb RH; Khoury G; Liotta LA
Cancer Res; 1987 Mar; 47(6):1523-8. PubMed ID: 3028610
[TBL] [Abstract][Full Text] [Related]
64. Polymorphic changes of cell phenotype caused by elevated expression of an exogenous NEU proto-oncogene.
Tarakhovsky AM; Resnikov M; Zaichuk T; Tugusheva MV; Butenko ZA; Prassolov VS
Oncogene; 1990 Mar; 5(3):405-10. PubMed ID: 1969137
[TBL] [Abstract][Full Text] [Related]
65. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.
Cohen JA; Weiner DB; More KF; Kokai Y; Williams WV; Maguire HC; LiVolsi VA; Greene MI
Oncogene; 1989 Jan; 4(1):81-8. PubMed ID: 2563577
[TBL] [Abstract][Full Text] [Related]
66. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus E1a gene products.
Yan DH; Chang LS; Hung MC
Oncogene; 1991 Feb; 6(2):343-5. PubMed ID: 1672040
[TBL] [Abstract][Full Text] [Related]
67. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185.
McKenzie SJ; Marks PJ; Lam T; Morgan J; Panicali DL; Trimpe KL; Carney WP
Oncogene; 1989 May; 4(5):543-8. PubMed ID: 2566965
[TBL] [Abstract][Full Text] [Related]
68. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon.
D'Emilia J; Bulovas K; D'Ercole K; Wolf B; Steele G; Summerhayes IC
Oncogene; 1989 Oct; 4(10):1233-9. PubMed ID: 2571966
[TBL] [Abstract][Full Text] [Related]
69. Molecular and biological properties of hamster tumor cell lines transformed with B77 virus: expression of v-src does not correlate with metastatic potential.
Kisseleva NP; Sabová L; Weismanová E
Neoplasma; 1991; 38(3):293-301. PubMed ID: 1713304
[TBL] [Abstract][Full Text] [Related]
70. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency.
Garcia M; Derocq D; Pujol P; Rochefort H
Oncogene; 1990 Dec; 5(12):1809-14. PubMed ID: 2284099
[TBL] [Abstract][Full Text] [Related]
71. Adenovirus E1a as a tumor-suppressor gene.
Chinnadurai G
Oncogene; 1992 Jul; 7(7):1255-8. PubMed ID: 1535700
[TBL] [Abstract][Full Text] [Related]
72. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.
Drebin JA; Link VC; Stern DF; Weinberg RA; Greene MI
Cell; 1985 Jul; 41(3):697-706. PubMed ID: 2860972
[TBL] [Abstract][Full Text] [Related]
73. Selection for transformation and met protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor alpha.
Hudziak RM; Lewis GD; Holmes WE; Ullrich A; Shepard HM
Cell Growth Differ; 1990 Mar; 1(3):129-34. PubMed ID: 2078501
[TBL] [Abstract][Full Text] [Related]
74. Forced expression of YL-1 protein suppresses the anchorage-independent growth of Kirsten sarcoma virus-transformed NIH3T3 cells.
Horikawa I; Tanaka H; Yuasa Y; Suzuki M; Shimizu M; Oshimura M
Exp Cell Res; 1995 Sep; 220(1):11-7. PubMed ID: 7664828
[TBL] [Abstract][Full Text] [Related]
75. [Role of p185c-erbB2 in endometrial cancer growth in vitro].
Sakamoto H; Ohtani K; Ohta H; Takami M; Takami T; Satoh K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jul; 44(7):800-4. PubMed ID: 1354238
[TBL] [Abstract][Full Text] [Related]
76. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
Zhang L; Lau YK; Xi L; Hong RL; Kim DS; Chen CF; Hortobagyi GN; Chang C; Hung MC
Oncogene; 1998 Jun; 16(22):2855-63. PubMed ID: 9671406
[TBL] [Abstract][Full Text] [Related]
77. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma.
Nanni P; Pupa SM; Nicoletti G; De Giovanni C; Landuzzi L; Rossi I; Astolfi A; Ricci C; De Vecchi R; Invernizzi AM; Di Carlo E; Musiani P; Forni G; Menard S; Lollini PL
Int J Cancer; 2000 Jul; 87(2):186-94. PubMed ID: 10861472
[TBL] [Abstract][Full Text] [Related]
78. Experimental metastatic ability of H-ras-transformed NIH3T3 cells.
Bondy GP; Wilson S; Chambers AF
Cancer Res; 1985 Dec; 45(12 Pt 1):6005-9. PubMed ID: 4063960
[TBL] [Abstract][Full Text] [Related]
79. Repression of SV40 T oncoprotein expression by DMSO.
Witte MM; Parker RF; Wang H; Scott RE
J Cell Physiol; 1992 Apr; 151(1):50-5. PubMed ID: 1373148
[TBL] [Abstract][Full Text] [Related]
80. Downstream signal transduction defects that suppress transformation in two revertant cell lines expressing activated rat neu oncogene.
Reardon DB; Hung MC
J Biol Chem; 1993 Aug; 268(24):18136-42. PubMed ID: 7688739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
